OR WAIT null SECS
September 13, 2025
Article
Research shows reduced risk of death, major adverse cardiovascular events, and myocardial infarction, and a non-significant reduction in stroke and cardiovascular death.
September 06, 2025
Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.
September 03, 2025
A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.
Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.
September 02, 2025
Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.
August 29, 2025
The 2025 Concise Clinical Guidance also aims to assuage vaccine hesitancy and resistance, provide better education, and overcome barriers to implementation.
August 23, 2025
A recent analysis utilizing the AHA’s PREVENT equations has found 11.8 million US adults aged 40 to 75 had a 10-year ASCVD risk of 5% or greater.
August 21, 2025
Preliminary findings have also indicated an association between an evolocumab add-on to statin therapy and stenosis degree reduction.
August 20, 2025
August 19, 2025
New research shines a light on the liver’s role in cardiovascular disease prevention, indicating a potential new predictor for coronary heart disease.
